Dizal (Jiangsu) Pharmaceutical Co., Ltd. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was CNY 735.37 million compared to CNY 669.88 million a year ago. Basic loss per share from continuing operations was CNY 1.82 compared to CNY 1.86 a year ago.
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Equities
688192
CNE1000055W8
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
39.64 CNY | -4.96% | +0.48% | -17.16% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-17.16% | 2.27B | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+0.73% | 22.78B | |
-10.63% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- 688192 Stock
- News Dizal (Jiangsu) Pharmaceutical Co., Ltd.
- Dizal Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022